Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Common Equity (2023 - 2025)

Metagenomi (MGX) has disclosed Common Equity for 3 consecutive years, with $158.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 32.47% to $158.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $158.6 million, a 32.47% decrease, with the full-year FY2025 number at $158.6 million, down 32.47% from a year prior.
  • Common Equity was $158.6 million for Q4 2025 at Metagenomi, down from $178.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $275.6 million in Q1 2024 to a low of -$135.6 million in Q4 2023.
  • A 3-year average of $121.1 million and a median of $187.1 million in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 214997.37% in 2024, then tumbled 32.47% in 2025.
  • Metagenomi's Common Equity stood at -$135.6 million in 2023, then surged by 273.22% to $234.9 million in 2024, then crashed by 32.47% to $158.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Common Equity are $158.6 million (Q4 2025), $178.4 million (Q3 2025), and $195.8 million (Q2 2025).